Eight US IPOs raised $3.3 billion this week, including four Chinese deals and three biotechs. iQIYI raised $2.3 billion, making it the largest Chinese IPO...read more
Genprex, which is developing gene-based nanoparticle therapies to treat cancer, announced that it expects to price its IPO in February 2018. The company originally filed an S-1 in 2017 for a "best efforts" offering; Renaissance Capital began tracking the company...read more
Genprex, which is developing gene therapies for cancer, set the price for its upcoming IPO at $5.00. The company plans to offer a minimum of 2.0 million shares and a maximum of 4.5 million shares. At the midpoint, Genprex would raise $17.5 million at a basic...read more
US IPO Weekly Recap: 8-IPO week caps record 1Q with a flurry of Chinese deals
Eight US IPOs raised $3.3 billion this week, including four Chinese deals and three biotechs. iQIYI raised $2.3 billion, making it the largest Chinese IPO...read more
Micro-cap gene therapy biotech Genprex prices $6 million IPO at $5
Genprex, which is developing gene-based nanoparticle therapies to treat cancer, raised $6.4 million by...read more
Cancer biotech Genprex scheduled to price $6.5 million IPO in February
Genprex, which is developing gene-based nanoparticle therapies to treat cancer, announced that it expects to price its IPO in February 2018. The company originally filed an S-1 in 2017 for a "best efforts" offering; Renaissance Capital began tracking the company...read more
Micro-cap gene therapy biotech Genprex sets IPO price at $5.00
Genprex, which is developing gene therapies for cancer, set the price for its upcoming IPO at $5.00. The company plans to offer a minimum of 2.0 million shares and a maximum of 4.5 million shares. At the midpoint, Genprex would raise $17.5 million at a basic...read more